Studies blood samples to find markers in bipolar disorder and schizophrenia
Collects blood samples from people with bipolar disorder or schizophrenia to study genes.
Plain-language title generated from the registry record
Registry title: Immuno-Genetic, Inflammation, Retro-Virus, Environment
Key facts
- Where
- Bordeaux, Créteil, Paris, and Pontoise, FranceSee the 6 sites
Where in France
- Psychiatry Department of Perrens HospitalBordeaux, FranceNot yet recruiting
- Clinical Investigations Center of Mondor HospitalCréteil, FranceTaking people
- Psychiatry Department of Mondor HospitalCréteil, FranceTaking people
- EPS Maison BlancheParis, FranceTaking people
- Psychiatry Department of Widal HospitalParis, FranceTaking people
- Psychiatry Department of R. Dubos HospitalPontoise, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pr. Marion Leboyer
- Trial code
- NCT02878408
- Record updated
- 22 May 2026
- Original description
Immunology combined to neurobiology now offer prominent tools to yield biomarkers, so far missing in psychiatry, and to design innovative treatment approaches based on the discovery of new molecular and cellular targets. As Bipolar Disorder and Schizophrenia are now known to be significantly associated with neuro-inflammation, the project I-GIVE will combine multidisciplinary approaches (clinical, viral, immunological, genetic) to explore a global hypothesis placing the Human Endogenous Retro-Virus, HERV-W, at the crossroads between susceptibility to environmental factors (such as winter-spring births, infections, urbanicity…) and genetic factors controlling immune responses.Read full original descriptionShow less
Immuno-Génétique, Inflammation, Retro-Virus, Environnement
Immunology combined to neurobiology now offer prominent tools to yield biomarkers, so far missing in psychiatry, and to design innovative treatment approaches based on the discovery of new molecular and cellular targets. As Bipolar Disorder and Schizophrenia are now known to be significantly associated with neuro-inflammation, the project I-GIVE will combine multidisciplinary approaches (clinical, viral, immunological, genetic) to explore a global hypothesis placing the Human Endogenous Retro-Virus, HERV-W, at the crossroads between susceptibility to environmental factors (such as winter-spring births, infections, urbanicity…) and genetic factors controlling immune responses.
Thus I-GIVE will allow identification of new biomarkers and their correlation with clinical profiles and immuno-inflammatory/immuno-genetic markers, and description of patho-physiological mechanisms of a psychiatric disorder. In addition, I-GIVE should help to design innovative treatments and foster personalized psychiatry tailored to the needs of each patient. Notably, monoclonal antibodies anti-HERV-W Env will be assessed in a preclinical model for their ability to slow, stop, or even reverse the progression of the psychosis in patients. I-GIVE project should thus lead to major results that will have strong impacts on the scientific community, pharmaceutical industries and, in a longer term, on improvement of patients suffering Bipolar Disorder or Schizophrenia and their family.
Inclusion: Bipolar disorder or Schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders IV).
Exclusion: Severe neurologic illness; Infectious disease within 4 precedent weeks (including HIV 1 et 2, Hepatite B, C); Refuse to have HIV and hepatite B et C tests or to be informed of their results; pregnant women; Vaccination within 4 precedent weeks; Immunosuppressing or immuno-modulating treatment.